# A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer

> **NCT00480246** · PHASE1 · COMPLETED · sponsor: **BioLineRx, Ltd.**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BL 1020
- **DRUG:** Perphenazine

## Key facts

- **NCT ID:** NCT00480246
- **Lead sponsor:** BioLineRx, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2009-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00480246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00480246, "A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00480246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*